Lenalidomide Clinical Trials
103 recruitingDrug
Phase 261Phase 330Phase 124Early Phase 12Phase 41Not Applicable1
Showing 1–20 of 103 trials
Recruiting
Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled55 locationsNCT04609046
Recruiting
Phase 1Phase 2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
City of Hope Medical Center50 enrolled3 locationsNCT05861050
Recruiting
Phase 1Phase 2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Multiple Myeloma
AbbVie602 enrolled34 locationsNCT06892522
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Multiple Myeloma
Mayo Clinic100 enrolled1 locationNCT06042725
Recruiting
Phase 1
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Adult T-cell Leukemia/LymphomaHTLV-1 InfectionAcute Adult T-Cell Leukemia/Lymphoma+1 more
National Cancer Institute (NCI)30 enrolled19 locationsNCT04301076
Recruiting
Phase 2
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Multiple MyelomaSmoldering Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Irene Ghobrial, MD52 enrolled3 locationsNCT05469893
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled86 locationsNCT06649812
Recruiting
Phase 3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)
University of Leeds1,226 enrolled5 locationsNCT07649525
Recruiting
Phase 1Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Multiple Myeloma
Karyopharm Therapeutics Inc300 enrolled25 locationsNCT02343042
Recruiting
Phase 3
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Multiple Myeloma
Canadian Cancer Trials Group570 enrolled28 locationsNCT06182774
Recruiting
Phase 1Phase 2
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Primary Central Nervous System LymphomaSecondary Central Nervous System LymphomaCNS Lymphoma
James Rubenstein35 enrolled1 locationNCT05351593
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Pfizer1,116 enrolled127 locationsNCT05623020
Recruiting
Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
Regeneron Pharmaceuticals317 enrolled42 locationsNCT05137054
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled266 locationsNCT06191744
Recruiting
Phase 2
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Reem Karmali34 enrolled1 locationNCT06723457
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled270 locationsNCT05552222
Recruiting
Phase 1
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC240 enrolled14 locationsNCT06768489
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Multiple Myeloma
Hoffmann-La Roche200 enrolled16 locationsNCT05583617